Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PVLA vs TVTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
PVLA Captures Overall Composite Edge (48.2 HOLD vs 60.4 BUY), While TVTX Leads 5–1 on Growth & Valuation Pillars
PVLA Overall Winner
6-Pillar Tally: PVLA 1 – 5 TVTX
Matrix Metrics: PVLA 4 – 6 TVTX
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Travere Therapeutics, Inc. (TVTX) on higher Unified Composite conviction (48.2/100 HOLD vs. 60.4/100 BUY) after splitting the core matrix 4–6 (led by Profitability & Quality), while TVTX wins 5–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus TVTX at $49.90 (9.3x Forward P/E, -3.1% operating margin).
- Composite vs. Pillar Nuance: While TVTX currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.1% operating margin) and revenue trajectory (+0.0% vs. +36.2% YoY).
- Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile TVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About PVLA vs TVTX
PVLA
Head-to-Head Winner
Palvella Therapeutics, Inc. Common Stock
$145.03
-4.89% 1D
Market Cap
$2.2B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.66β · 75% Vol
Unified Composite Score
48.2
HOLD
Tech 35.0
Fund 53.0
Flow 67.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
TVTX
Travere Therapeutics, Inc. Common Stock
$49.90
-1.48% 1D
Market Cap
$4.9B
TTM Revenue
$651M
Forward P/E
9.3x
Beta / 30D Vol
1.39β · 44% Vol
Unified Composite Score
60.4
BUY
Tech 47.0
Fund 58.0
Flow 64.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (PVLA 1 – 5 TVTX)
1. Valuation Multiples
TVTX
Forward P/E
N/M
9.3x
Trailing P/E
N/M
25.8x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
8.4x
2. Growth & Scale
TVTX
Revenue Growth (YoY)
+0.0%
+36.2%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$651M
Market Cap
$2.2B
$4.9B
3. Profitability & Quality
PVLA
Gross Margin
N/A
61.1%
Operating Margin
0.0%
-3.1%
Net Profit Margin
0.0%
-18.7%
Return on Equity (ROE)
-63.4%
-321.2%
4. Balance Sheet & Cash Flow
TVTX
Cash Generation (TTM)
-$43M
-$27M
Cash Flow Margin
N/A
-4.2%
Net Cash / Leverage
$193M Net Cash
$493M Net Debt (27.28x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
TVTX
Options Structure Phase
CONSOLIDATION
CONSOLIDATION
Current IV / %ile
47.9% (2nd %ile)
39.1% (6th %ile)
Put/Call OI Skew
3.82x (Put-Skewed)
0.05x (Call-Skewed)
OBV Trend / Tech Phase
DISTRIBUTION · Neutral
ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat
TVTX
OpEx & R&D Intensity
N/A
64.2% of Rev ($418M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: PVLA (4) vs TVTX (6)| Institutional Metric | PVLA | TVTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $2.2B | $4.9B | TVTX | |
| Trailing P/E Ratio | N/M | 25.8x | TVTX | |
| Forward P/E Ratio | N/M | 9.3x | TVTX | |
| Revenue Growth (YoY) | +0.0% | +36.2% | TVTX | |
| Operating Margin (TTM) | 0.0% | -3.1% | PVLA | |
| Net Profit Margin | 0.0% | -18.7% | PVLA | |
| Return on Equity (ROE) | -63.4% | -321.2% | PVLA | |
| 52-Week Range Position | 68% ($72–$180) | 59% ($23–$69) | PVLA | |
| Beta / 30D Volatility | 1.66β · 75% Vol | 1.39β · 44% Vol | TVTX | |
| Unified Institutional Score | 48.2 / 100 (HOLD) | 60.4 / 100 (BUY) | TVTX | |
| Trailing 12M Revenue (USD) | N/A | $651M | Scale | |
| Gross Profit Margin (TTM) | N/A | 61.1% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 8.4x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$43M ($193M Net Cash) | -$27M ($493M Net Debt (27.28x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
PVLA +19.96 pp
3M Horizon
PVLA +18.33 pp
6M Horizon
PVLA +21.72 pp
1Y Horizon
PVLA +32.92 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PVLA Revenue | TVTX Revenue | PVLA Op. Margin | TVTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $30M | $160M | -113.1% | -48.7% | TVTX |
| FY2019 | $40M | $180M | -62.2% | -78.3% | PVLA |
| FY2020 | $30M | $200M | -115.7% | -88.8% | TVTX |
| FY2021 | $30M | $130M | -165.0% | -151.3% | TVTX |
| FY2022 | $30M | $110M | -167.8% | -292.2% | PVLA |
| FY2023 | $40M | $150M | -27.7% | -267.2% | PVLA |
| FY2024 | N/A | $230M | N/A | -138.9% | TVTX |
| FY2025 | N/A | $490M | N/A | -12.8% | TVTX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
PVLA
CONSOLIDATION
Current IV
47.9%
IV Percentile
2nd %ile
Put/Call OI Skew
3.82x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
DISTRIBUTION
Exact PVLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
TVTX
CONSOLIDATION
Current IV
39.1%
IV Percentile
6th %ile
Put/Call OI Skew
0.05x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact TVTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
PVLA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
TVTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
64.2% of Rev ($418M)
90D Engineering Disclosures
0 Published
Investor FAQ PVLA vs TVTX Key Questions & Quantitative Answers
As of Nov 16, 2026, Palvella Therapeutics, Inc. (PVLA) captures the overall head-to-head institutional edge over Travere Therapeutics, Inc. (TVTX) on higher Unified Composite conviction (48.2/100 HOLD vs. 60.4/100 BUY) after splitting the core matrix 4–6 (led by Profitability & Quality), while TVTX wins 5–1 across the 6-pillar growth and valuation breakdown. PVLA trades at $145.03 (N/M Forward P/E, 0.0% operating margin) versus TVTX at $49.90 (9.3x Forward P/E, -3.1% operating margin). Composite vs. Pillar Nuance: While TVTX currently prints a higher short-term Unified Composite Score (60.4/100 BUY vs. PVLA 48.2/100 HOLD), PVLA captures the overall institutional head-to-head verdict (4–6 matrix metrics and 1–5 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -3.1% operating margin) and revenue trajectory (+0.0% vs. +36.2% YoY). Technical & Structure Timing Caution: PVLA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.9); meanwhile TVTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TVTX leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with TVTX at +36.2% YoY revenue growth and +0.0% YoY earnings growth on $651M TTM revenue (61.1% gross margin, -3.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PVLA cumulative revenue shifted +33.3% while TVTX shifted +206.2%. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus 64.2% of Rev ($418M) (0 disclosures) for TVTX.
TVTX screens cheaper on headline valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas TVTX trades at 9.3x Forward P/E, 25.8x Trailing P/E, N/M PEG, and 8.4x EV/Revenue (-4.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus TVTX (-321.2% ROE) capital efficiency.
In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, TVTX carries 39.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.39β · 44% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
TVTX vs PVLA · Reverse Pair
PVLA vs ORKA
· Sector Peer
PVLA vs DNTH
· Sector Peer
PVLA vs SYRE
· Sector Peer
TVTX vs MIRM
· Sector Peer
TVTX vs VRDN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem